Abbott Laboratories (NYSE:ABT) soared 0.80% during previous trade, a total of 7.25M shares exchanged hands compared with its average trading volume of 8.45M shares whereas its relative volume is 0.87. The stock has a market capitalization of $55.11B along with 1.47B outstanding shares. Stock’s intraday price range hit the peak level of $38.08 and touched the lowest level of $37.60.
Most recently Abbott Laboratories (NYSE:ABT)’s price target was revised on 11/18/16 and according to 13 analysts stock’s price will reach at $47.38 during 52 weeks with standard deviation of 1.76. Stock’s minimum price target estimates has been figured out at $43 while the maximum price target forecast is established at $50, if we look at the price target with an optimistic approach it has upside potential of 25% from its latest closing price of $37.90.
Historically, if we look at price target revisions, two weeks ago Abbott Laboratories (NYSE:ABT)’s price target was revised on 11/14/16 by the analysts, however the bullish price estimates of the stock set at $50 while the bearish estimates kept at $45 over the next one year. Stock’s 52-week target was retained at $48.18, the estimates indicates a standard deviation of 1.78.
While taking an overview of recommendation trends, the stock currently has an average brokerage recommendation of 1.60. ABR value is precisely based on brokerage recommendations, where out of 15 brokerage recommendations 10 rate Abbott Laboratories (NYSE:ABT) stock a Strong Buy, 1 rate the stocks of the company a Buy, 4 rate Hold, 0 rate Sell and 0 recommend a Strong Sell. Most recently on 6/21/16 the stock of Abbott Laboratories (NYSE:ABT) upgraded by Edward Jones from Hold to Buy. However previously on 1/4/16 it was downgraded by Morgan Stanley from Overweight to Equal-Weight. A research note issued on 11/13/15 the stock was downgraded by Goldman from Buy to Neutral.
Abbott Laboratories (NYSE:ABT) performance over the past one year plunged -12% whereas its year to date (YTD) performance indicated a bearish trend of -13.48%. During the last six months the stock slipped -2.03%. Quarterly performance of the company shows declining momentum of -9.38% while its last one month trend is negative with -2.07%. Stock’s weekly performance expressed down trend of -3.22%.
The company’s price sits -6.10% below from its 50-day moving average of $39.67 and -6.41% below from the stock’s 200-day moving average which is $40.96. Abbott Laboratories (NYSE:ABT)’s shares are currently trading -16.70% away from the 52-week high price of $45.50 and +7.25% far from the 52-week low price of $35.34.
According to consensus agreement of 13 analysts Abbott Laboratories (NYSE:ABT) will report earnings per share of $0.65 in their quarterly report and it is expected to announce the company’s results on 1/26/17. For the current quarter the company has high EPS estimates of $0.66 in contradiction of low EPS estimates of $0.64. However a year ago for the same quarter the company has reported $0.62 EPS. Current year EPS projections for Abbott Laboratories (NYSE:ABT) set at $2.21 according to the sentiments of 17 analysts, while its lowest earnings estimates are $2.19 and highest earnings estimates are $2.23.
According to 12 analysts, Abbott Laboratories (NYSE:ABT)’s revenue estimates for the current quarter are $5.41B meanwhile the company has high revenue estimates of $5.44B in contradiction of low revenue estimates of $5.35B. For the current year the company’s revenue estimates are $20.93B compared to low analyst estimates of $20.87B and high estimates of $20.96B according to the projection of 15 analysts.